Atlas Trials

Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene

Clinical trial NCT06291935 · RECRUITING

Trial details

NCT number
NCT06291935
Sponsor
VeonGen Therapeutics GmbH
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Retinitis Pigmentosa
Start date
2023-09-01
Primary completion
2026-04-01
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.